Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors

被引:42
作者
De Ronchi, D
Faranca, I
Berardi, D
Scudellari, P
Borderi, N
Manfredi, R
Fratiglioni, L
机构
[1] Univ Bologna, Div Infect Dis, Dept Clin & Expt Med, Bologna, Italy
[2] Karolinska Inst, Div Geriatr Epidemiol, NEUROTEC, Stockholm, Sweden
[3] Univ Bologna, Inst Psychiat, Bologna, Italy
关键词
D O I
10.1001/archneur.59.5.812
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Context: Although it is well established that acquired immunodeficiency syndrome dementia complex mainly develops in patients with advanced human immunodeficiency virus 1 (HIV-1) infection and severe immunosuppression, other factors that might increase the risk of early neuropsychological abnormalities are controversial. Objective: To identify risk factors for HIV-1-related cognitive impairment. Design: Case-control study. Setting: Division of Infectious Diseases, University of Bologna. Participants: We studied 272 consecutive individuals: 90 HIV-1-seronegative, 88 asymptomatic HIV-1-seropositive, and 94 symptomatic HIV-1-seropositive persons. Main Outcome Measures: Cognitive impairment was defined as poor performance on at least 2 of the 7 neuropsychological tests included in the battery. Cutoff scores for poor performance on a test were established as 2 or more SDs tower than the mean of the seronegative group in the corresponding risk behavior strata: injecting drug users, hemophiliacs, and other risk behaviors. The following risk factors were studied: age, sex, education, risk behaviors, HIV-1 stage, lymphocyte count, and antiretroviral therapy. Results: Compared with individuals with higher levels of education, those with less than 6 years of schooling had an odds ratio (OR) of 17.2 (95% confidence interval [CI], 3.6-83.3) for cognitive impairment, independent of age, sex, disease stage, antiretroviral therapy, and risk behavior. Compared with injecting drug users, homosexual/bisexual and heterosexual participants had ORs of 9.6 (95% CI, 2.2-42.7) and 6.3 (95% CI, 2.2-18.3), respectively, for cognitive impairment. Use of antiretroviral treatment (any vs none) was associated with lower prevalence of cognitive impairment (OR, 0.1; 95% CI, 0.0-0.3). Compared with persons with high CD4(+) cell counts (greater than or equal to500/muL), those with low (<200/mu L) and moderate (200-499/mu L) CD4(+) cell counts had adjusted ORs of 8.6 (95% CI, 1.0-71.0) and 6.9 (95% CI, 1.0-48.4), respectively. The presence of prominent depressive symptoms did not change the results. Conclusions: Low educational level, low CD4(+) cell count, and homosexual/bisexual and heterosexual risk behaviors are risk factors for cognitive impairment in HIV-1-seropositive persons. Antiretroviral therapy exerts a beneficial effect against cognitive impairment in symptomatic individuals. Homosexual/bisexual and heterosexual persons who survive longer are expected to be the group at highest risk for cognitive impairment. However, the protective effect of antiretroviral therapy may balance this increased risk.
引用
收藏
页码:812 / 818
页数:7
相关论文
共 56 条
[31]   NEUROLOGIC AND NEUROPSYCHOLOGICAL MANIFESTATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN INTRAVENOUS-DRUG-USERS WITHOUT ACQUIRED-IMMUNODEFICIENCY-SYNDROME - RELATIONSHIP TO HEAD-INJURY [J].
MARDER, K ;
STERN, Y ;
MALOUF, R ;
TANG, MX ;
BELL, K ;
DOONEIEF, G ;
ELSADR, W ;
GOLDSTEIN, S ;
GORMAN, J ;
RICHARDS, M ;
SANO, M ;
SORRELL, S ;
TODAK, G ;
WILLIAMS, JBW ;
EHRHARDT, A ;
MAYEUX, R .
ARCHIVES OF NEUROLOGY, 1992, 49 (11) :1169-1175
[32]   RISK OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-RELATED NEUROLOGIC DISEASE IN A COHORT OF INTRAVENOUS-DRUG-USERS [J].
MARDER, K ;
LIU, XH ;
STERN, Y ;
MALOUF, R ;
DOONEIEF, G ;
BELL, K ;
TODAK, G ;
JOSEPH, M ;
SORRELL, S ;
SADR, WE ;
WILLIAMS, JBW ;
EHRHARDT, A ;
STEIN, Z ;
GORMAN, J .
ARCHIVES OF NEUROLOGY, 1995, 52 (12) :1174-1182
[33]   DEMENTIA IN AIDS PATIENTS - INCIDENCE AND RISK-FACTORS [J].
MCARTHUR, JC ;
HOOVER, DR ;
BACELLAR, H ;
MILLER, EN ;
COHEN, BA ;
BECKER, JT ;
GRAHAM, NMH ;
MCARTHUR, JH ;
SELNES, OA ;
JACOBSON, LP ;
VISSCHER, BR ;
CONCHA, M ;
SAAH, A ;
PALENICEK, J ;
ARMENIAN, H ;
FARZADEGAN, H ;
MARGOLICK, J ;
PHAIR, JP ;
CHMIEL, JS ;
BAUER, K ;
VARIAKOJIS, D ;
WESCH, J ;
WOLINSKY, SM ;
DETELS, R ;
CHEN, I ;
DUDLEY, J ;
FAHEY, JL ;
GIORGI, JV ;
MARTINEZMAZA, O ;
NISHANIAN, P ;
TAYLOR, J ;
ZACK, J ;
RINALDO, CR ;
KINGSLEY, L ;
GUPTA, P ;
HO, M ;
MUNOZ, A ;
BEATY, T ;
GALAI, N ;
MEINERT, C ;
NELSON, K ;
PIANTADOSI, S ;
SEMINARA, D ;
SU, S ;
SCHRAGER, L ;
VERMUND, SH ;
KASLOW, RA ;
VANRADEN, MJ ;
OBRAMS, I .
NEUROLOGY, 1993, 43 (11) :2245-2252
[34]   Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].
Michaels, SH ;
Clark, R ;
Kissinger, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) :405-406
[35]  
MILLER L, 1985, Journal of Substance Abuse Treatment, V2, P5, DOI 10.1016/0740-5472(85)90017-0
[36]   EDUCATION AND DEMENTIA - RESEARCH EVIDENCE SUPPORTS THE CONCEPT USE IT OR LOSE IT [J].
ORRELL, M ;
SAHAKIAN, B .
BMJ-BRITISH MEDICAL JOURNAL, 1995, 310 (6985) :951-952
[37]   Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].
Palella, FJ ;
Delaney, KM ;
Moorman, AC ;
Loveless, MO ;
Fuhrer, J ;
Satten, GA ;
Aschman, DJ ;
Holmberg, SD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860
[38]   Cognitive deficits and emotional disorders in HIV-1 infected individuals [J].
Poutiainen, E .
ACTA PSYCHIATRICA SCANDINAVICA, 1995, 92 (06) :429-435
[39]   Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy [J].
Price, RW ;
Yiannoutsos, CT ;
Clifford, DB ;
Zaborski, L ;
Tselis, A ;
Sidtis, JJ ;
Cohen, B ;
Hall, CD ;
Erice, A ;
Henry, K .
AIDS, 1999, 13 (13) :1677-1685
[40]   Neurological complications of HIV infection [J].
Price, RW .
LANCET, 1996, 348 (9025) :445-452